Arsanis’ (NASDAQ:ASNS) quiet period will end on Tuesday, December 26th. Arsanis had issued 4,000,000 shares in its initial public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. During Arsanis’ quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
A number of equities research analysts have issued reports on ASNS shares. Cowen started coverage on Arsanis in a research report on Monday, December 11th. They issued an “outperform” rating on the stock. Citigroup started coverage on Arsanis in a research report on Monday, December 11th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Piper Jaffray Companies started coverage on Arsanis in a research report on Monday, December 11th. They issued an “overweight” rating and a $23.00 price target on the stock.
Shares of Arsanis (NASDAQ:ASNS) opened at $12.70 on Monday. The stock has a market capitalization of $138.50 and a PE ratio of -6.20. Arsanis has a 12-month low of $10.40 and a 12-month high of $19.73.
Arsanis Company Profile
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.